 SINGAPORE, March 01, 2021 GLOBE NEWSWIRE -- ASLAN Pharmaceuticals Nasdaq: ASLN, a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has commenced an underwritten public offering of 60.0 million of its American Depositary Shares ADSs representing ordinary shares. In addition, ASLAN expects to grant the underwriters a 30-day option to purchase up to an additional 9.0 million of ADSs in the public offering on the same terms and conditions. All ADSs to be sold in the offering will be offered by ASLAN. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. 